Previous 10 | Next 10 |
Results indicate that 12 months after carotid intervention the CGuard EPS MicroNET-covered stent delivers sustained protection against postprocedural neurologic events TEL AVIV, Israel, June 10, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard...
TEL AVIV, Israel, June 08, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease, announced today the closing, on June 5, 2020, of its $11.5 milli...
InspireMD (NYSEMKT: NSPR ) has priced its public offering of 22,222,200 units at $0.45/unit for expected gross proceeds of ~$10M. More news on: InspireMD, Inc., Healthcare stocks news, , Stocks on the move, Read more ...
TEL AVIV, Israel, June 03, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease, today announced the pricing of an underwritten public offering of 22,...
InspireMD, Inc. (NSPR) Q1 2020 Earnings Conference Call May 12, 2020 08:30 AM ET Company Participants Jeremy Feffer - Investor Relations Marvin Slosman - Chief Executive Officer Craig Shore - Chief Financial Officer Conference Call Participants Presentation Operator ...
InspireMD (NYSEMKT: NSPR ): Q1 GAAP EPS of -$0.43. More news on: InspireMD, Inc., Earnings news and commentary, Stocks on the move, Healthcare stocks news, , Read more ...
First quarter revenue growth driven by continued strong uptake of the CGuard ™ Embolic Prevention System (EPS) in the company’s major markets Management to host investor conference call today, May 12, at 8:30am ET TEL AVIV, Israel, May 12, 2020 (GLOBE NEWSWIRE) -- Ins...
TEL AVIV, Israel, May 05, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease, announced today that management will host a conference call and webcast on...
InspireMD, Inc. (NSPR) Q4 2019 Earnings Conference Call March 10, 2020 08:30 AM ET Company Participants Jeremy Feffer – Investor Relations Marvin Slosman – Chief Executive Officer Craig Shore – Chief Financial Officer Conference Call Participants Vernon...
Robust CGuard™ EPS year-over-year revenue growth of 31% Management to host investor conference call today, March 10, at 8:30am ET TEL AVIV, Israel, March 10, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention...
News, Short Squeeze, Breakout and More Instantly...
-Conference call and webcast to be held at 8:30 a.m. EDT- TEL AVIV, Israel, and MIAMI, July 30, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease and stroke prev...
Series H warrants exercisable following release of positive outcomes results related to one-year follow-up from the Company’s C-GUARDIANS pivotal trial. Participating warrant holders include Marshall Wace, OrbiMed, Rosalind, Nantahala, Soleus, Velan, and certain InspireMD Board m...
Data demonstrate lowest reported primary endpoint event rate of 1.95% through twelve months post-procedure for any carotid stent or embolic protection device pivotal trial Study results to support a Premarket Approval (PMA) application to FDA in H2 2024 U.S. commercial launch of...